北京热景生物技术股份有限公司关于出售已回购股份进展公告

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. is progressing with the sale of repurchased shares to maintain company value and shareholder rights, following regulatory guidelines [2][3]. Group 1: Share Repurchase Overview - The company repurchased a total of 2,893,010 shares from February 8, 2024, to May 7, 2024, representing 3.12% of the current total share capital [2]. - The repurchased shares will be sold through centralized bidding within twelve months after the announcement of the repurchase results [2]. Group 2: Sale Plan Progress - The company plans to sell up to 1,854,158 shares through centralized bidding from January 19, 2026, to July 18, 2026 [3]. - The sale plan was approved during the fourth board meeting on December 23, 2025, in accordance with the repurchase report [3]. Group 3: Sale Implementation Details - The company is required to disclose the sale progress at the beginning of each month, adhering to regulatory requirements [5]. - The sale plan is consistent with previously disclosed plans and commitments, with no major events like stock splits or mergers planned during the sale period [5]. Group 4: Impact of the Sale - The sale aligns with the company's established plan and relevant regulations, with proceeds intended to supplement the company's working capital [6].